Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Exercise Pill is No Replacement for Exercise

By Drug Discovery Trends Editor | August 6, 2008

Recently, researchers at the Salk Institute for Biological Studies published a study in the journal Cell on the results of a substance that increased exercise endurance without daily exertion when tested in mice. Media reports have described this substance as an “exercise pill,” potentially eliminating the need for exercise. Frank Booth, a University of Missouri expert on the science of inactivity, says the “exercise pill” study did not test all of the commonly known benefits of exercise and taking the pill cannot be considered a replacement for exercise.

In the Cell paper “Exercise Mimetics” the researchers demonstrated that AMPK-PPAR? pathways, which is a cellular messenger system, can be targeted by orally active drugs to enhance training adaptation or even to increase endurance without exercise. However, Booth cautions that some of the commonly known benefits of exercise were not tested in the Cell paper including:

• Decreased resting and submaximal exercise heart rate
• Increased heart stroke volume at all exercise work loads
• Increased maximal exercise cardiac output
• Lower blood pressure and arterial stiffness
• Increased aerobic capacity

Until targeting AMPK-PPAR? pathways by drugs is shown to have all the above listed exercise benefits in humans, it is premature to use the term “exercise mimetics” from the very limited observations of the paper, Booth said. Booth’s expectation, based upon his more than 40 years of research experience in exercise and physical inactivity adaptations, is that the drugs in the Cell paper will only partially imitate exercise. In order for any “exercise pill” to counter physical inactivity, the pill must be polygenic, or control many genes at once; therefore the drugs are not likely to provide all of the benefits of comprehensive physical activity. In Booth’s opinion, the drugs used in the Cell paper were not conclusively proven to mimic exercise, contrary to media reports.

Release date: August, 4 2008
Source: University of Missouri


Filed Under: Drug Discovery

 

Related Articles Read More >

FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE